Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Good morning. We have a lot of news this morning that we’ll get straight into.
Regenxbio trials halted after brain tumor found in patient
The FDA paused trials for two experimental gene therapies from Regenxbio after one child developed a brain tumor, the company said this morning.
Continue to STAT+ to read the full story…
STAT Pharma: The science and business of new drug development
Leave a Reply